Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Mike Czapar-- Senior Vice President, Investor Relations Good morning. Thank you for joining us for Eli Lilly and Company's Q4 2024 earnings call. I'm Mike Czapar, senior vice president of investor ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Eli Lilly stock rose Thursday despite lighter-than-expected sales of its weight-loss and diabetes drugs Zepbound and Mounjaro.